Date | Price Target | Rating | Analyst |
---|---|---|---|
9/19/2024 | $42.00 → $50.00 | Neutral | UBS |
9/5/2024 | $40.00 → $57.00 | Hold → Buy | Craig Hallum |
3/4/2024 | $70.00 → $42.00 | Neutral → Sell | UBS |
2/14/2024 | $66.00 → $37.00 | Neutral → Underweight | JP Morgan |
12/11/2023 | $95.00 → $72.00 | Buy → Neutral | Citigroup |
12/12/2022 | $90.00 → $125.00 | Neutral → Buy | Citigroup |
12/7/2022 | $125.00 | Outperform | RBC Capital Mkts |
10/14/2022 | $86.00 | Sell → Neutral | UBS |
UBS resumed coverage of QuidelOrtho with a rating of Neutral and set a new price target of $50.00 from $42.00 previously
Craig Hallum upgraded QuidelOrtho from Hold to Buy and set a new price target of $57.00 from $40.00 previously
UBS downgraded QuidelOrtho from Neutral to Sell and set a new price target of $42.00 from $70.00 previously
144 - QuidelOrtho Corp (0001906324) (Subject)
10-Q - QuidelOrtho Corp (0001906324) (Filer)
8-K - QuidelOrtho Corp (0001906324) (Filer)
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. (NYSE:T) rose during Wednesday's session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down 0.4% year over year and missing the analyst consensus estimate of $29.9 billion. Adjusted EPS of 57 cents is in line with the analyst consensus estimate, according to data from Benzinga Pro. AT&T shares gained 3.1% to $18.78 on Wednesday. Here are some other big stocks recording gains in today’s session. PROG Holdings, Inc. (NYSE:PRG) shares jumped 20.4% to $41.71 after the company reported better-than-expected s
JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.
QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.
QuidelOrtho Receives FDA 510(k) Clearance for its VITROS Syphilis Assay QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") has received U.S. Food and Drug Administration ("FDA") 510(k) clearance for its VITROS syphilis assay as part of its menu, strengthening QuidelOrtho's position as a leader in infectious disease testing. Using the automated VITROS systems, this assay is intended for the qualitative determination of total (IgG and IgM) antibodies to Treponema pallidum (TP)-specific antigens in human serum and plasma using the automated VITROS 3600, 5600 and XT 7600 systems. The presence of antibodies to TP-specific antigens, in conjunction with non-treponemal laboratory tests and cli
QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend two upcoming investor conferences. Morgan Stanley 22nd Annual Global Health Conference – New York, NY On Thursday, September 5, 2024, QuidelOrtho's President and Chief Executive Officer, Brian Blaser, and Chief Financial Officer, Joseph Busky, are scheduled to participate in a fireside chat at 7:00 a.m. ET / 4:00 a.m. PT. 2024 Baird Global Healthcare Conference – New York, NY On Tuesday, September 10, 2024, Messrs. Blaser and
4 - QuidelOrtho Corp (0001906324) (Issuer)
4 - QuidelOrtho Corp (0001906324) (Issuer)
3 - QuidelOrtho Corp (0001906324) (Issuer)
QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.
NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 14, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL). investors that a lawsuit was filed on behalf of investors that purchased QuidelOrtho securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors'
4 - QuidelOrtho Corp (0001906324) (Issuer)
— $100 million in annualized cost-savings initiatives will benefit second half 2024 and first half 2025 — — Strong progress on business review and refocusing R&D investments on core growth areas — Second quarter 2024 revenue was $637 million, as reported: Total recurring revenue1 grew 3% as reported and 5% in constant currency compared to the prior year period, excluding COVID-19 revenue and U.S. Donor Screening revenue YTD 2024 revenue was $1.35 billion, as reported: Total recurring revenue1 grew 6% as reported and 7% in constant currency compared to the prior year period, excluding COVID-19 revenue, a one-time third-party collaboration settlement and U.S. Donor Screening rev
QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2024 ended June 30, 2024, after the market close on Wednesday, July 31, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call on the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.co
- Global year-over-year revenue growth of 5% as reported and 6% in constant currency, excluding COVID-19 revenue - - Cost reduction initiatives well underway, headcount reductions expected to deliver approximately $100 million in annualized savings - - Company suspends 2024 financial guidance while it assesses business under new President and Chief Executive Officer - First Quarter 2024 Results and Recent Highlights Revenue was $711 million, as reported: Non-respiratory revenue was flat at $574 million compared to the prior year period, as reported and in constant currency Excluding the one-time third-party settlement of $21 million in the prior year period, non-respiratory revenue
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)
SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)